NOVELTY - Use of G protein-coupled receptor 101 (GPRlOl) inhibitor, antagonist or inverse agonist is claimed for prevention and/or therapeutic treatment of diseases selected from the group consisting of acromegaly and gigantism. USE - The Used for prevention and/or therapeutic treatment of diseases selected from group consisting of acromegaly and gigantism, for reducing hormone secretion from the hypothalamus and pituitary gland, and used in controlling the growth of a pituitary tumor, where the tumor secretes functional hormone or no functional hormones, and GPRlOl agonist used in preventive and/or therapeutic treatment of disorders selected from the group consisting of dwarfism, short stature, hypopituitarism, and a disease of low levels of pituitary hormone secretion caused due to growth hormone deficiency (all claimed). DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for: (1) a method for reducing hormone secretion from the hypothalamus and pituitary gland in a subject, which involves administering a GPRlOl antagonist; (2) a method for reducing hormone production by a pituitary tumor or hyperplasia in a subject, which involves administering a GPR101 antagonist; (3) a method for reducing the growth velocity of a subject with a pituitary tumor or hyperplasia, which involves administering a GPR101 antagonist. where the tumor or hyperplasia causes growth hormone over-secretion and increased height (the clinical disease of gigantism); (4) a method for reducing hormone production by a pituitary tumor or hyperplasia, where tumor or hyperplasia over-secretes growth hormone and leads to the clinical disease of acromegaly, which involves administering a GPR101 antagonist; (5) a method for reducing hormone production by a pituitary tumor or hyperplasia where the tumor or hyperplasia over-secretes prolactin (prolactinoma), causes Cushing's disease due to an adrenocorticotropic hormone (ACTH) secreting pituitary tumor, or a thyroid stimulating hormone (TSH) secreting pituitary adenoma, or pituitary tumors secreting a variety of different hormones, which involve administering a GPR101 antagonist; (6) a method for controlling the growth of a pituitary tumor, which involves administering a GPR101 antagonist; (7) a method for increasing hormone production from the hypothalamus and pituitary gland in a subject, which involves stimulating hormone production by administering a GPR101 agonist; (8) a method for increasing hormone production by the hypothalamus and pituitary in a subject with hypopituitarism and low levels of pituitary hormone secretion, which involves stimulating hormone production by administering a GPR101 agonist; (9) a method for increasing hormone production by the hypothalamus and pituitary in a subject with dwarfism or short stature due to growth hormone deficiency, which involves stimulating growth hormone production by administering a GPR101 agonist; (10) a method for increasing the growth velocity of a subject with dwarfism or short stature, which involves stimulating growth by administering a GPR101 agonist; (11) a GHRH inhibitor, antagonist or inverse agonist for the therapeutic treatment of X-linked acrogigantism (X-LAG syndrome); (12) a GH antagonist for use in the therapeutic treatment of X-linked acrogigantism (X-LAG syndrome); (13) a method for increasing body mass and/or body size of lifestock, which involves administering the livestock with an effective amount of GPR101 agonist; and (14) a non-human transgenic animal, which comprises an expressed transgene encoding GPR101 or over-expressing endogenous GPR101 gene.
Use of G protein-coupled receptor 101 inhibitor, antagonist or inverse agonist for prevention and/or therapeutic treatment of diseases selected from group consisting of acromegaly and gigantism
TRIVELLIN G
2016-01-01
Abstract
NOVELTY - Use of G protein-coupled receptor 101 (GPRlOl) inhibitor, antagonist or inverse agonist is claimed for prevention and/or therapeutic treatment of diseases selected from the group consisting of acromegaly and gigantism. USE - The Used for prevention and/or therapeutic treatment of diseases selected from group consisting of acromegaly and gigantism, for reducing hormone secretion from the hypothalamus and pituitary gland, and used in controlling the growth of a pituitary tumor, where the tumor secretes functional hormone or no functional hormones, and GPRlOl agonist used in preventive and/or therapeutic treatment of disorders selected from the group consisting of dwarfism, short stature, hypopituitarism, and a disease of low levels of pituitary hormone secretion caused due to growth hormone deficiency (all claimed). DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for: (1) a method for reducing hormone secretion from the hypothalamus and pituitary gland in a subject, which involves administering a GPRlOl antagonist; (2) a method for reducing hormone production by a pituitary tumor or hyperplasia in a subject, which involves administering a GPR101 antagonist; (3) a method for reducing the growth velocity of a subject with a pituitary tumor or hyperplasia, which involves administering a GPR101 antagonist. where the tumor or hyperplasia causes growth hormone over-secretion and increased height (the clinical disease of gigantism); (4) a method for reducing hormone production by a pituitary tumor or hyperplasia, where tumor or hyperplasia over-secretes growth hormone and leads to the clinical disease of acromegaly, which involves administering a GPR101 antagonist; (5) a method for reducing hormone production by a pituitary tumor or hyperplasia where the tumor or hyperplasia over-secretes prolactin (prolactinoma), causes Cushing's disease due to an adrenocorticotropic hormone (ACTH) secreting pituitary tumor, or a thyroid stimulating hormone (TSH) secreting pituitary adenoma, or pituitary tumors secreting a variety of different hormones, which involve administering a GPR101 antagonist; (6) a method for controlling the growth of a pituitary tumor, which involves administering a GPR101 antagonist; (7) a method for increasing hormone production from the hypothalamus and pituitary gland in a subject, which involves stimulating hormone production by administering a GPR101 agonist; (8) a method for increasing hormone production by the hypothalamus and pituitary in a subject with hypopituitarism and low levels of pituitary hormone secretion, which involves stimulating hormone production by administering a GPR101 agonist; (9) a method for increasing hormone production by the hypothalamus and pituitary in a subject with dwarfism or short stature due to growth hormone deficiency, which involves stimulating growth hormone production by administering a GPR101 agonist; (10) a method for increasing the growth velocity of a subject with dwarfism or short stature, which involves stimulating growth by administering a GPR101 agonist; (11) a GHRH inhibitor, antagonist or inverse agonist for the therapeutic treatment of X-linked acrogigantism (X-LAG syndrome); (12) a GH antagonist for use in the therapeutic treatment of X-linked acrogigantism (X-LAG syndrome); (13) a method for increasing body mass and/or body size of lifestock, which involves administering the livestock with an effective amount of GPR101 agonist; and (14) a non-human transgenic animal, which comprises an expressed transgene encoding GPR101 or over-expressing endogenous GPR101 gene.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
